Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 17 | 2025 | 1866 | 2.410 |
Why?
|
| Vancomycin | 8 | 2025 | 92 | 1.900 |
Why?
|
| Osteomyelitis | 2 | 2025 | 143 | 1.580 |
Why?
|
| Outpatients | 5 | 2024 | 425 | 1.120 |
Why?
|
| Gram-Positive Bacterial Infections | 2 | 2025 | 69 | 1.000 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2025 | 8 | 0.910 |
Why?
|
| Enterococcus faecium | 1 | 2025 | 21 | 0.900 |
Why?
|
| Teicoplanin | 2 | 2021 | 15 | 0.880 |
Why?
|
| Arthritis, Infectious | 1 | 2025 | 73 | 0.840 |
Why?
|
| Adenosine Monophosphate | 1 | 2024 | 73 | 0.840 |
Why?
|
| Alanine | 1 | 2024 | 159 | 0.820 |
Why?
|
| Ritonavir | 2 | 2023 | 72 | 0.800 |
Why?
|
| Organ Transplantation | 2 | 2024 | 252 | 0.740 |
Why?
|
| beta-Lactamases | 1 | 2022 | 50 | 0.710 |
Why?
|
| Invasive Fungal Infections | 1 | 2021 | 11 | 0.690 |
Why?
|
| Aspergillosis | 1 | 2021 | 22 | 0.690 |
Why?
|
| Candidiasis | 1 | 2021 | 62 | 0.680 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 2 | 2021 | 237 | 0.660 |
Why?
|
| Antiviral Agents | 3 | 2024 | 748 | 0.630 |
Why?
|
| Microbial Sensitivity Tests | 6 | 2023 | 367 | 0.600 |
Why?
|
| Staphylococcal Infections | 2 | 2021 | 390 | 0.590 |
Why?
|
| Acute Kidney Injury | 3 | 2024 | 822 | 0.570 |
Why?
|
| Blood Coagulation Factors | 1 | 2018 | 54 | 0.560 |
Why?
|
| Hospitalization | 4 | 2024 | 2264 | 0.500 |
Why?
|
| Tetracyclines | 3 | 2025 | 14 | 0.490 |
Why?
|
| Cephalosporins | 3 | 2024 | 45 | 0.420 |
Why?
|
| Sepsis | 1 | 2020 | 627 | 0.410 |
Why?
|
| Hemorrhage | 1 | 2018 | 788 | 0.390 |
Why?
|
| Retrospective Studies | 16 | 2025 | 16447 | 0.390 |
Why?
|
| Kidney | 2 | 2023 | 1482 | 0.380 |
Why?
|
| Critical Illness | 1 | 2019 | 852 | 0.370 |
Why?
|
| Wounds and Injuries | 1 | 2019 | 917 | 0.340 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 254 | 0.340 |
Why?
|
| Humans | 31 | 2025 | 141284 | 0.320 |
Why?
|
| Antibodies, Viral | 2 | 2024 | 654 | 0.310 |
Why?
|
| Treatment Outcome | 6 | 2025 | 11216 | 0.290 |
Why?
|
| Immunocompromised Host | 2 | 2025 | 201 | 0.250 |
Why?
|
| Aged | 10 | 2025 | 24836 | 0.240 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 124 | 0.230 |
Why?
|
| Adult | 12 | 2025 | 39319 | 0.220 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2024 | 21 | 0.220 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2024 | 9 | 0.210 |
Why?
|
| Recurrence | 2 | 2025 | 1108 | 0.210 |
Why?
|
| Health Care Rationing | 1 | 2024 | 60 | 0.210 |
Why?
|
| Cystitis | 1 | 2024 | 23 | 0.210 |
Why?
|
| Aminoglycosides | 1 | 2024 | 26 | 0.210 |
Why?
|
| beta-Lactams | 2 | 2023 | 36 | 0.210 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 4 | 2025 | 78 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 2 | 2023 | 321 | 0.200 |
Why?
|
| Immune Reconstitution | 1 | 2023 | 8 | 0.200 |
Why?
|
| Endocarditis | 1 | 2024 | 38 | 0.200 |
Why?
|
| Endocarditis, Bacterial | 1 | 2024 | 46 | 0.200 |
Why?
|
| Lactams | 1 | 2023 | 27 | 0.200 |
Why?
|
| Middle Aged | 9 | 2025 | 34658 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2023 | 1043 | 0.190 |
Why?
|
| Acinetobacter Infections | 1 | 2022 | 13 | 0.190 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 24 | 0.190 |
Why?
|
| Proline | 1 | 2023 | 80 | 0.190 |
Why?
|
| Leucine | 1 | 2023 | 117 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 3 | 2024 | 1456 | 0.190 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 101 | 0.180 |
Why?
|
| Pseudomonas Infections | 1 | 2024 | 225 | 0.180 |
Why?
|
| Nitriles | 1 | 2023 | 189 | 0.180 |
Why?
|
| Klebsiella pneumoniae | 1 | 2022 | 46 | 0.180 |
Why?
|
| Mycobacterium abscessus | 1 | 2023 | 117 | 0.180 |
Why?
|
| Creatinine | 2 | 2023 | 491 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2023 | 197 | 0.180 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2024 | 357 | 0.170 |
Why?
|
| Renal Insufficiency | 1 | 2023 | 170 | 0.170 |
Why?
|
| Clostridium Infections | 1 | 2022 | 74 | 0.170 |
Why?
|
| Daptomycin | 1 | 2021 | 18 | 0.170 |
Why?
|
| Plasmids | 1 | 2022 | 365 | 0.170 |
Why?
|
| Antifungal Agents | 1 | 2021 | 144 | 0.160 |
Why?
|
| Salvage Therapy | 1 | 2021 | 154 | 0.160 |
Why?
|
| Male | 12 | 2025 | 70140 | 0.160 |
Why?
|
| Burns | 1 | 2023 | 350 | 0.150 |
Why?
|
| Machine Learning | 1 | 2024 | 555 | 0.140 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2023 | 363 | 0.140 |
Why?
|
| Female | 11 | 2025 | 75814 | 0.140 |
Why?
|
| Vitamin K | 1 | 2018 | 47 | 0.140 |
Why?
|
| Hemostatics | 1 | 2018 | 60 | 0.140 |
Why?
|
| Isoantibodies | 1 | 2017 | 56 | 0.130 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 670 | 0.130 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2023 | 626 | 0.130 |
Why?
|
| Colorado | 2 | 2024 | 4599 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2017 | 232 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 2904 | 0.120 |
Why?
|
| Bacterial Proteins | 1 | 2022 | 913 | 0.120 |
Why?
|
| Graft Survival | 1 | 2017 | 502 | 0.110 |
Why?
|
| Graft Rejection | 1 | 2017 | 545 | 0.110 |
Why?
|
| Logistic Models | 1 | 2019 | 2098 | 0.100 |
Why?
|
| Cystic Fibrosis | 1 | 2023 | 1124 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2019 | 868 | 0.100 |
Why?
|
| Emergency Service, Hospital | 1 | 2024 | 2210 | 0.090 |
Why?
|
| Transplant Recipients | 2 | 2024 | 181 | 0.090 |
Why?
|
| Risk Factors | 3 | 2024 | 10490 | 0.090 |
Why?
|
| Heart Transplantation | 1 | 2017 | 714 | 0.090 |
Why?
|
| Standard of Care | 2 | 2022 | 77 | 0.090 |
Why?
|
| Bacteremia | 2 | 2024 | 218 | 0.080 |
Why?
|
| Quality of Life | 1 | 2021 | 3024 | 0.070 |
Why?
|
| Subcutaneous Tissue | 1 | 2024 | 25 | 0.050 |
Why?
|
| Skin Transplantation | 1 | 2024 | 84 | 0.050 |
Why?
|
| United States Food and Drug Administration | 1 | 2024 | 197 | 0.050 |
Why?
|
| Viremia | 1 | 2024 | 154 | 0.050 |
Why?
|
| Gram-Negative Bacteria | 1 | 2023 | 79 | 0.050 |
Why?
|
| Piperacillin | 1 | 2023 | 7 | 0.050 |
Why?
|
| Acetates | 1 | 2023 | 82 | 0.050 |
Why?
|
| Carbapenems | 1 | 2022 | 25 | 0.050 |
Why?
|
| Minocycline | 1 | 2022 | 27 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2023 | 163 | 0.050 |
Why?
|
| Quinazolines | 1 | 2023 | 260 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2022 | 355 | 0.040 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2023 | 205 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2024 | 312 | 0.040 |
Why?
|
| Health Policy | 1 | 2024 | 385 | 0.040 |
Why?
|
| Gentamicins | 1 | 2021 | 51 | 0.040 |
Why?
|
| Rifampin | 1 | 2021 | 81 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 367 | 0.040 |
Why?
|
| Glomerular Filtration Rate | 1 | 2023 | 755 | 0.040 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 175 | 0.040 |
Why?
|
| Skin | 1 | 2024 | 760 | 0.040 |
Why?
|
| Incidence | 1 | 2024 | 2809 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2024 | 1129 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 910 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1505 | 0.030 |
Why?
|
| Flow Cytometry | 1 | 2017 | 1182 | 0.030 |
Why?
|
| Adolescent | 2 | 2024 | 22116 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1449 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2024 | 7805 | 0.020 |
Why?
|
| Obesity | 1 | 2022 | 3007 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 2205 | 0.020 |
Why?
|
| Young Adult | 1 | 2024 | 13727 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 4180 | 0.020 |
Why?
|
| Infant, Newborn | 1 | 2017 | 6270 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 9820 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2017 | 11511 | 0.010 |
Why?
|
| Child | 1 | 2017 | 22390 | 0.010 |
Why?
|